Endotracheal Tolazoline Administration in Neonates with Persistent Pulmonary Hypertension

Journal of Perinatology

Volumn 17, Issue 6, 1997, Pages 461-464

  Parida, Saroj K ^a,b   Baker, Sheri ^a   Kuhn, Robert ^a   Desai, Nirmala ^a   Pauly, Thomas H ^a  

^a UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON DIOXIDE; TOLAZOLINE; VASODILATOR AGENT;

ARTICLE; ARTIFICIAL VENTILATION; BIRTH WEIGHT; BLOOD; BLOOD GAS ANALYSIS; DOSE RESPONSE; ENDOTRACHEAL INTUBATION; GESTATIONAL AGE; HUMAN; INHALATIONAL DRUG ADMINISTRATION; NEWBORN; PERSISTENT FETUS CIRCULATION; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; BIRTH WEIGHT; BLOOD GAS ANALYSIS; CARBON DIOXIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; GESTATIONAL AGE; HUMANS; INFANT, NEWBORN; INTUBATION, INTRATRACHEAL; PERSISTENT FETAL CIRCULATION SYNDROME; RESPIRATION, ARTIFICIAL; TOLAZOLINE; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 0031264039     PISSN: 07438346     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Gersony WM, Duc GV, Sinclair JC. "PFC" syndrome (persistence of the fetal circulation). Circulation 1969;40(suppl III):87.
2. Siassi B, Goldberg SJ, Emmanouilides GC, Higashimo SM, Lewis E. Persistent pulmonary vascular obstruction in newborn infants. J Pediatr 1971;78:610-5.
3. Riemenschneider TA, Neilsen HC, Rutenberg HD, Jaffe RB. Disturbance of the transitional circulation: spectrum of pulmonary hypertension and myocardial dysfunction. J Pediatr 1976;89:622.
4. John E, Roberts V, Burnard E. Persistent pulmonary hypertension of the newborn treated with hyperventilation: clinical features and outcome. Austr Pediatr J 1988;24:357-61.
5. Hageman JR, Carrasco NJM, Risenberg H. Persistent pulmonary hypertension of the newborn. Am J Dis Child 1984;138:592-5.
6. Goetzman BW, Riemenschneider TA. Persistence of the fetal circulation. Pediatr Rev 1980;2:37-40.
7. Wegeman ME. Annual summary of vital statistics - 1990. Pediatrics 1991;88:1081-92.
8. Walsh Sukys MC. Persistent pulmonary hypertension of the newborn. The black box revisited. Clin Perinatol 1993;20:127-43.
9. Stevenson DK, Kasting DS, Darnall RA, Ariagno RL, Johnson JD, Malachowski N, et al. Refractory hypoxemia associated with neonatal pulmonary disease: the use and limitations of tolazoline. J Pediatr 1979;95:595-9.
10. Curtis J, O'Neill T, Pettett G. Endotracheal administration of tolazoline in hypoxia-induced pulmonary hypertension. Pediatrics 1993;92:403-8.
11. Greenberg MI. The use of endotracheal medication in cardiac emergencies. Resuscitation 1984;12:155-65.
12. Zaritsky A. Pediatric resuscitation pharmacology. Members of the Medication in Pediatric Resuscitation Panel. Ann Emerg Med 1993;22:445-55.
13. Geggel R, Reid L. The structural basis of PPHN. Clin Perinatol 1984;11:525-49.
14. Reid L. Structure and function in pulmonary hypertension: new perceptions. Chest 1989;140:1490-3.
15. Adams R, Gardner TH. Persistent pulmonary hypertension of the newborn. Am J Dis Child 1984;138:592-5.
16. Wille L, Ulmer HE, Obladen M. Persistence of fetal circulation in the newborn. J Perinat Med 1981;9:106-9.
17. Fox W, Duara S. Persistent pulmonary hypertension in the neonate: diagnosis and management. J Pediatr 1983;103:505-14.
18. Gersony WM, Due GV, Adams A, Gardner TH. Persistent pulmonary hypertension of the newborn. Am J Dis Child 1984;138:592-5.
19. Levin DL, Heymann MA, Kitterman JA, Gregory GA, Phibbs RH, Rudolph AM. Persistent pulmonary hypertension of the newborn infant. J Pediatr 1976;89:626-30.
20. Gouyon JB, Francoise M. Vasodilators in persistent pulmonary hypertension of the newborn: a need for optimal appraisal of efficacy. Dev Pharmacol Ther 1992;19:62-8.
21. Ford WDA, Sen S, Barker AP, Lee CM. Pulmonary hypertension in lambs with congenital diaphragmatic hernia: vasodilator prostaglandins, isoprenaline, and tolazoline. J Pediatr Surg 1990;25:487-91.
22. Wung JT, James LS, Kilchevsky E, James E. Management of infants with severe respiratory failure and persistence of the fetal circulation, without hyperventilation. Pediatrics 1985;76:488-94.
23. Geggel RL. Inhalational nitric oxide: a selective pulmonary vasodilator for treatment of persistent pulmonary hypertension of the newborn. J Pediatr 1993;123:76-9.
24. Kinsella JP, Abman SH. Inhalational nitrous oxide therapy for persistent pulmonary hypertension of the newborn. Pediatrics 1993;91:997-8.
25. Zayek M, Cleveland D, Morin FC. Treatment of persistent pulmonary hypertension in the newborn lamb by inhalational nittous oxide. J Pediatr 1993;122:743-50.
26. Giacoia GP. Nitric oxide: a selective pulmonary vasodilator. South Med J 1995;88:33-41.
27. Ward RM. Pharmacology of tolazoline. Clin Perinatol 1984;11:703-13.
28. Goetzman BW, Milstein JD. Pulmonary vasodilator action of tolazoline. Pediatr Res 1979;13:942-4.
29. Goetzman BW, Sunshine P, Johnson JD, Wennberg RP, Hackel A, Merten DF, et al. Neonatal hypoxia and pulmonary vasospasm: response to tolazoline. J Pediatr 1976;89:617-21.
30. Schranz D, Zepp F, Iversen S, Wippermann C, Huth R, Zimmer B, et al. Effects of tolazoline and prostacyclin on pulmonary hypertension in infants after cardiac surgery. Crit Care Med 1992;20:1243-9.
31. Hill SJ. Distribution, properties, and functional characteristics of three classes of histamine receptors. Pharmacol Rev 1990;42:45-83.
32. Ward RM, Daniel CH, Kendig JW, Wood MA. Oliguria and tolazoline pharmacokinetics in the newborn. Pediatrics 1986;77:307-15.